AnaptysBio Inc., a clinical-stage biotechnology company, announced positive results from its Phase 2b trial of rosnilimab, an investigational drug targeting PD-1+ T cells, in patients with moderate-to-severe rheumatoid arthritis $(RA)$. The trial demonstrated that rosnilimab achieved efficacy comparable to JAK inhibitors, with improvements in clinically meaningful measures such as low disease activity and remission over a six-month period. The drug also showed favorable safety and tolerability profiles compared to standard biologics or JAKs, with durable responses lasting at least two months after discontinuation. AnaptysBio will host an investor call and webcast to discuss the findings on June 3, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.